The revenue miss and EPS shortfall are likely to pressure MGX shares near-term, especially given the $53M market cap and 78% analyst bullishness creating downside risk. Watch for any updates on MGX-001 IND timing or partnership announcements that could offset the weak quarter.
Price Chart
Executive Summary
Metagenomi reported Q1 2026 EPS of -$0.61, missing consensus of -$0.55 by 10.9%, and collaboration revenue of $1.25M, well below the $5.9M consensus. The company highlighted $140.2M cash runway through Q4 2027 and reiterated its timeline for MGX-001 IND submission in Q4 2026, but the revenue miss and continued operating losses overshadow the pipeline progress.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.61 vs consensus -$0.55 (10.9% miss)
- Collaboration revenue $1.25M vs consensus $5.9M (78.8% miss)
- Cash and securities $140.2M as of March 31, 2026, down from $160.8M at year-end 2025
- R&D expenses fell to $19.3M from $25.1M YoY; G&A flat at $6.5M
- Net loss -$23.1M vs -$25.0M in Q1 2025
- MGX-001 IND submission on track for Q4 2026 with clinical trials expected in 2027
- Cash runway expected to support operations through Q4 2027
Financial Impact
EPS miss of ~$0.06 and revenue miss of ~$4.65M vs consensus; cash burn of ~$20.6M in Q1
Risk Factors
- Revenue miss of 78.8% vs consensus signals potential partnership delays or reduced collaboration activity
- Cash burn of ~$20.6M per quarter implies ~6.8 quarters of runway, but no new financing disclosed
- Pre-revenue biotech with no approved products; all value depends on MGX-001 clinical success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292307 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 21, 2026 5w ago | 8-K | $1.14 $0.8310 | ▼ −27.11% | ▼ −26.55% | $0.8000 (−29.82%) |
Aug 10, 2026 11w ago | 8-K | $1.21 $1.15 | ▲ +4.96% | ▲ +3.90% | $0.8000 (+33.88%) |
Jun 10, 2026 19w ago | Insider Cluster | $1.23 $1.26 | ▲ +2.44% | ▼ −1.18% | $0.8000 (−34.96%) |
Jun 10, 2026 19w ago | Insider Cluster | $1.23 $1.26 | ▲ +2.44% | ▼ −1.18% | $0.8000 (−34.96%) |
Jun 10, 2026 19w ago | Insider Cluster | $1.23 $1.26 | ▲ +2.44% | ▼ −1.18% | $0.8000 (−34.96%) |
Jun 10, 2026 19w ago | Insider Cluster | $1.23 $1.26 | ▲ +2.44% | ▼ −1.18% | $0.8000 (−34.96%) |
Jun 10, 2026 19w ago | Insider Cluster | $1.23 $1.26 | ▲ +2.44% | ▼ −1.18% | $0.8000 (−34.96%) |
May 11, 2026 24w ago | 8-K | $1.35 $1.23 | ▼ −8.89% | ▼ −7.16% | $0.8000 (−40.74%) |
May 11, 2026 24w ago | Press Release | $1.35 $1.23 | ▲ +8.89% | ▲ +7.16% | $0.8000 (+40.74%) |
Apr 27, 2026 26w ago | DEFA14A | $1.44 $1.36 | ▼ −5.56% | ▼ −11.02% | $0.8000 (−44.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers